{"id":390528,"date":"2018-12-12T00:00:00","date_gmt":"2018-12-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2018-biopharma-acute-myeloid-leukemia-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-30T11:25:07","modified_gmt":"2026-04-30T11:25:07","slug":"dlsfon0016-2018-biopharma-acute-myeloid-leukemia-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2018-biopharma-acute-myeloid-leukemia-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Acute Myeloid Leukemia | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Acute myeloid leukemia (<abbr title=\"acute myeloid leukemia\">AML<\/abbr>) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically,\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0treatment has been dominated by chemotherapy followed by allo-<abbr title=\"stem-cell transplantation\">SCT<\/abbr>\u00a0in eligible patients. However, following a flurry of drug approvals in 2017 and 2018, the\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0treatment landscape is undergoing a transformation. The entry of novel agents into the treatment paradigm will enable the\u00a0increasingly personalized treatment of patients, based on the characteristics of their disease and specific biomarkers. However, several areas of unmet need remain. Notably, patients unfit for intensive chemotherapy induction and relapsed\/refractory\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>patients offer significant commercial opportunity for innovative agents.<\/p>\n<p>Label expansions and new drug approvals (e.g.,\u00a0<abbr title=\"fms-like tyrosine kinase 3\">FLT3<\/abbr>\u00a0inhibitors,\u00a0apoptosis-inducing agents) will fuel substantial growth of the\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0therapy market over the 2017-2027 forecast period. This report provides insight on how treatment options for\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0are likely to change over the 2017-2027 forecast period. It also analyzes the current and future earnings potential of AML therapies.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li><b>What are the key drivers of growth over this period? What will be the major constraints on therapy sales? What are the drug development activities of note? What challenges and opportunities remain?<\/b><\/li>\n<li><b>What is thought-leader opinion of emerging therapies and\u00a0drug classes? For which patient populations will these agents be positioned? Will second-generation\u00a0<abbr title=\"fms-like tyrosine kinase 3\">FLT3<\/abbr>inhibitors receive approval in the markets under study? How will use of these agents affect prescribing of other agents for\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>?<\/b><\/li>\n<li><b>How do key opinion leaders view the use of emerging therapies in the maintenance setting? Will maintenance therapy become a part of standard\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0treatment in the future?<\/b><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><strong>Markets covered<\/strong>: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research<\/strong>: 17 country-specific interviews with thought leaders.<\/p>\n<p><strong>Epidemiology<\/strong>: Diagnosed incident cases of de novo\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0and\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>\u00a0with\u00a0<abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>-related changes.<\/p>\n<p><strong>Population segments in market forecast<\/strong>: First-line\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>, younger patients (aged < 60); first-line\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>, older patients (aged \u2265 60); second-line\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>, younger patients (aged < 60); second-line\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>, older patients (aged \u2265 60); third-line\u00a0<abbr title=\"acute myeloid leukemia\">AML<\/abbr>.<\/p>\n<p><strong>Emerging therapies<\/strong>: Phase III: 11 drugs; Phase II: 27 drugs.<\/p>\n","protected":false},"template":"","class_list":["post-390528","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390528\/revisions"}],"predecessor-version":[{"id":576675,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390528\/revisions\/576675"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}